Neurology in Massachusetts

BrainsWay

BrainsWay is a global leader in noninvasive neurostimulation treatments for mental health disorders, founded in 2003 and dual-listed on NASDAQ and the Tel Aviv Stock Exchange. Headquartered in Burlington, MA, and Jerusalem, the company develops and commercializes its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology, utilizing patented H-Coil helmets for targeted brain stimulation. The Deep TMS™ system is the flagship offering, providing noninvasive treatment through electromagnetic pulses to stimulate deeper brain regions. It is FDA-cleared for major depressive disorder, obsessive-compulsive disorder, and smoking addiction. BrainsWay is committed to advancing neuroscience to improve mental health, emphasizing awareness and access to treatment options, particularly for those who do not respond to traditional therapies. The company also supports healthcare providers with education on the efficacy of its devices and protocols.

Beacon Biosignals is an AI-driven neurotechnology company specializing in clinical-grade sleep EEG capture and biomarker analysis for drug development and clinical research. The company develops FDA-cleared headband devices (Dreem 3S) that collect high-fidelity sleep electroencephalography data in home and clinical settings, paired with proprietary AI algorithms trained on 200,000+ hours of EEG recordings. Beacon's end-to-end platform supports translational research, clinical trial optimization, and real-world clinical practice across psychiatric disorders (major depressive disorder, schizophrenia, bipolar disorder), neurological conditions, and primary and secondary sleep disorders. The company provides quantitative sleep endpoints and pharmacodynamic biomarkers to identify dose-dependent drug effects, characterize and stratify patient populations, support label expansion claims, and track disease progression. Services include full-service clinical trial support with Clinical Study Operations and Scientific Services teams managing device setup, software integration, data quality assurance, and regulatory reporting. Beacon's technology enables objective measurement of sleep architecture and brain function, reducing participant and site burden compared to traditional methods. The platform integrates secure data upload, low-latency event monitoring for compliance and treatment response assessment, and analytics for cohort identification. Beacon is backed by significant venture funding (Series B upsized to $97 million+ as of April 2026) and serves pharmaceutical development, clinical research organizations, and academic institutions. Products are restricted to clinical trial, diagnostic, and academic research use and are not available for individual consumer purchase.

PASCALL SYSTEMS INC. is a Boston-based medical device company specializing in precision EEG-guided anesthesia management. The company develops a wearable brain monitoring platform that uses advanced signal processing and electroencephalography (EEG) to optimize intraoperative anesthetic administration. The platform aims to reduce unnecessary anesthetic exposure, thereby improving postoperative outcomes and preventing complications such as postoperative delirium (POD) and opioid dependence. The technology integrates real-time physiological data analysis, control engineering, and AI-driven decision support to empower anesthesiologists with personalized, data-driven anesthesia dosing. PASCALL's solution is designed to comply with FDA regulations and operates under rigorous quality management systems. The company focuses on signal extraction, artifact removal, and state-space modeling of brain activity to deliver clinically actionable insights during surgery.

Ives EEG Solutions, Inc. manufactures and supplies EEG electrodes and electrode harness systems for clinical, research, and veterinary applications. Founded in 1995, the company specializes in disposable conductive plastic electrodes (DCPE), electrode harnesses, subdermal wire electrodes, and MR/CT-compatible electrode kits. Products are designed for intensive care units (ICUs), epilepsy monitoring units (EMUs), and long-term EEG monitoring. The company emphasizes skin-safe, child-friendly electrode designs to minimize skin breakdown in neonates and sensitive-skin patients. All products are manufactured to support EEG accuracy and cost-effectiveness for hospitals and clinical centers. The company serves hospitals, clinics, research institutions, and veterinary centers globally. Ives EEG Solutions is preferred by EEG technologists for product quality, ease of use, and customer service. The firm also offers free product samples and expert consultation services to support customer needs.

Empatica is a digital health company specializing in FDA-cleared wearable devices and clinical-grade digital biomarker platforms for remote patient monitoring and clinical research. The company develops continuous health monitoring solutions that collect physiological data from everyday life, with particular expertise in neurological applications including epilepsy monitoring and Parkinson's disease assessment. Empatica's Health Monitoring Platform is an end-to-end remote monitoring solution designed for clinical trials, providing raw data collection and validated digital biomarkers across multiple therapeutic areas. The platform features over 300 digital measures derived from wearable sensors, supporting objective monitoring of motor symptoms, seizure detection, and treatment response. Empatica holds 8 FDA clearances and CE MDR certification. The company's wearable devices, including the EmbraceMini and EpiMonitor, are deployed across 160+ countries in over 40 languages. More than half of the top 20 pharmaceutical companies use the Empatica platform for clinical trial monitoring and digital endpoint development. The technology has been referenced in over 12,000 research publications. Empatica serves pharmaceutical companies, contract research organizations, academic medical centers, and healthcare systems requiring objective, continuous health data collection outside traditional clinical settings.

Rebion, Inc. commercializes Neural Performance Scanning (NPS), a proprietary technology platform that measures neurophysiologic mechanisms of the optic nerve/brain continuum through retinal scanning. The company's primary product, Blinq®, is an FDA-cleared portable point-of-care neural performance scanner designed for pediatric vision screening. Blinq directly detects micro-strabismus and amblyopia (lazy eye) by quantifying bilateral fixation and saccadic eye movements, achieving up to 100% sensitivity and over 90% specificity in clinical evaluations. The device performs a 3-second neural performance scan capable of detecting binocularity impairments associated with as little as 1-degree misalignment. Rebion's technology is supported by peer-reviewed clinical studies and research conducted at major medical institutions. The company also develops Traq™, an investigational device leveraging NPS to measure visual tracking impairments for clinical research purposes (currently not available for sale in the United States). Rebion serves diverse markets including community screeners, schools and administrators, clinical staff, parents, and caregivers. The platform enables early disease detection, intervention, and customized treatment across clinics, schools, and public health initiatives, reducing unnecessary referrals while improving diagnostic accuracy and patient outcomes.

Enlight Medical Technologies is a global medical technology company headquartered in Boston, Massachusetts, with research and development centers and manufacturing facilities in Boston, San Francisco, Shanghai, Beijing, and Shenzhen. The company specializes in interventional medical devices for structural heart disease, vascular intervention, and neuromodulation products. The company's core therapeutic areas include: (1) valve intervention—addressing mitral regurgitation and other valvular pathologies through catheterization-based approaches; (2) aortic and peripheral intervention—treating aortic dissection and peripheral vascular disease; (3) neuromodulation—using electrode stimulation for Parkinson's disease, epilepsy, chronic pain, and urinary incontinence; and (4) brain-computer interface (BCI) technology for neurological applications and functional enhancement. The company also develops life science and diagnostic platforms, including proteomic analysis tools aligned with the Human Protein Atlas initiative. Enlight Medical maintains GMP-certified manufacturing facilities and operates across both passive and active device platforms with AI imaging capabilities. The company holds multiple medical device licenses in China and has multiple advanced clinical-stage or submitted products. Research and development teams have 15+ years of medical device engineering and production management experience. The company was founded in Boston and has expanded significantly in China, serving structural heart disease and neuromodulation markets. As of 2023, a spinoff entity (Yinghe Brain Science) completed a Series A funding round focused on next-generation neuromodulation and BCI technology development.

BioSensics is a wearable sensor and digital health technology company founded in 2007 by three Harvard University scientists. The company specializes in developing FDA-registered medical devices and digital biomarkers for clinical trials, remote patient monitoring, and health assessments, particularly for older adults and neurological disorders. BioSensics' core offerings include advanced fall detection and prevention systems with automatic fall alert capabilities, continuous monitoring of fall risk and physical activity, balance and gait assessment technologies, and cognitive function monitoring sensors. The company also provides the BioDigit Home platform, a centralized data aggregation system that integrates data from various digital health technologies. BioSensics has licensed its fall detection technology to major retailers and medical device manufacturers and provides comprehensive operational and technical services for clinical research across therapeutic areas including Alzheimer's disease, Parkinson's disease, and stroke. With over $50 million in NIH funding support, BioSensics has established itself as a leader in objective measurement of disease symptoms and validated biomarkers for clinical and research applications.

Diagnosys LLC is a specialized manufacturer of visual electrophysiology test systems for both preclinical research and clinical ophthalmology practice. With over 40 years of market presence, the company designs and manufactures hardware and software for measuring visual function through electroretinography (ERG), pattern electroretinography (PERG), visually evoked potentials (VEP), and related electrophysiological testing modalities. The company's product portfolio spans three major categories: (1) Preclinical systems, including the proprietary Celeris® platform for rodent testing with dual-function stimulator-electrodes and ERG solutions for small to large animals; (2) Clinical visual function test systems encompassing visual electrophysiology, visual psychophysical testing, objective acuity measurement, and pupillometry; and (3) Trial services including study setup assistance, operator training, and quality assurance data review for multi-site clinical research. Diagnosys serves a global customer base that includes leading academic medical centers, eye institutes, and specialty ophthalmology practices such as Mayo Clinic, Bascom Palmer Eye Institute, Cleveland Clinic, Moorfields Eye Hospital, and Wilmer Eye Institute. The systems are used across multiple ophthalmology subspecialties: retina (inherited retinal diseases), glaucoma, pediatric ophthalmology, and neuro-ophthalmology. The company also actively supports clinical trial infrastructure with 35+ years of trial services experience. Key capabilities include in-house hardware and software design, patented and trademarked platforms, and extensive clinical validation across academic and research institutions worldwide. The company participates in major scientific conferences (ARVO, Society for Neuroscience) and provides continuing education webinars on visual electrophysiology methodology.

Neuroelectrics develops a cloud-based, personalized neuromodulation platform (Starstim) for treating brain disorders including refractory focal epilepsy and treatment-resistant depression. The platform integrates three modular components: a multi-channel transcranial electrical stimulation (tES) headpiece for EEG monitoring and neuromodulation, cloud-based secure remote treatment delivery, and AI-driven personalization based on computational neuroscience, data science, and patient physiological data. The company's approach targets dysfunctional neural circuits holistically rather than single brain nodes, offering a non-invasive, non-drug therapeutic option for patients unresponsive to pharmacological or surgical interventions. Starstim hardware and research tools are widely used in neuroscience research, with hundreds of published papers utilizing the platform. The company is conducting pivotal clinical trials in refractory focal epilepsy (NCT04770337) and pilot studies in at-home depression treatment (NCT05205915). Neuroelectrics serves both clinical therapeutic and research markets, with regulatory clearance for investigational use in multiple jurisdictions.

Cumulus Neuroscience develops NeuLogiq®, a medical-grade, at-home digital data collection and analytics platform for functional brain health monitoring and central nervous system (CNS) disease management. The platform combines a 510(k)-cleared novel EEG headset with tablet-based cognitive, mood, language, and sleep assessments, synced to cloud-based machine learning analytics. NeuLogiq enables frequent longitudinal monitoring in clinical and home settings, designed to address challenges in CNS drug discovery including late diagnosis, patient stratification, and treatment monitoring. The company serves pharmaceutical companies conducting clinical trials through its Cumulus Pharma Advisory Group (CPAG), a paid-in consortium that includes ten major global pharmaceutical companies: Biogen, GSK, Pfizer, Eli Lilly, Takeda, Bristol Myers Squibb, Boehringer Ingelheim, Merck, Roche, and J&J Innovative Medicine. Several CPAG members have active studies using the NeuLogiq Platform. The platform assesses discrete brain functions including working memory, episodic memory, executive function, decision-making, neuronal integrity, network connectivity, emotional bias, speech characteristics, and sleep metrics. The company employs approximately 30 engineers, scientists, and business professionals, backed by experienced life science and technology investors including the Dementia Discovery Fund, as well as UK and EU innovation agencies. Regulatory clearance includes FDA 510(k) for the EEG headset. NeuLogiq integrates third-party validated algorithms for facial expression recognition, language analysis, and sleep staging.

ACRA-CUT, Inc., located in Acton, Massachusetts, is a specialized manufacturer of neurosurgical instruments founded in 1981. The company is recognized as a leader in the research, development, and manufacture of cranial perforators for open neurosurgery. ACRA-CUT designs and produces a comprehensive range of cranial perforators in multiple models and sizes to address bone variations in both adult and pediatric procedures. Their product portfolio includes the ACRA-CUT Scalp Clip System, a reusable scalp clip gun with disposable clip cartridges in various clamping forces for hemostasis in both adult and pediatric applications. The company also manufactures spiral cranioblades optimized for low-speed applications, hand instruments including dura separators, cranioblade kits, and distraction screws for neurosurgical applications. Product lines include Smart Drill, Express 100, and Express 120 models. ACRA-CUT serves neurosurgeons, surgical centers, and hospital operating rooms in the United States. The company maintains a strong commitment to manufacturing safety and product design quality for neurosurgical patients. While specific regulatory certifications are not detailed on the fetched site content, the company's long operational history and surgical instrument focus suggest compliance with applicable medical device regulations.

machineMD AG is a medical device company founded at the University Hospital of Bern, Switzerland, specializing in non-invasive neuroophthalmological diagnostic equipment. The company develops neos®, a proprietary neurophthalmoscope platform designed for automated, quantitative assessment of eye movements, pupils, and visual fields. neos® enables standardized, objective measurement of neuroophthalmological function across primary, secondary, and tertiary care settings, reducing operator variability and extending specialist-level diagnostic capability to underserved clinical environments. The platform incorporates quantitative pupillometry and oculometric analysis with demonstrated clinical applications across neurological and ophthalmological indications including multiple sclerosis, myasthenia gravis, Parkinson's disease, Alzheimer's disease, Huntington's disease, stroke, traumatic brain injury, age-related macular degeneration, and other neurodegenerative and neuro-ophthalmological conditions. machineMD operates facilities in Bern, Switzerland (headquarters at Weyermannsstrasse 36, 3008 Bern) and Cambridge, Massachusetts (1 Broadway, Cambridge, MA 02142). The company maintains active clinical partnerships with major Swiss academic hospitals including University Hospital Lucerne (LUKS), Inselspital Bern, and Universitätsspital Zürich, and international collaborations. Regulatory pathway and specific FDA/CE certification status not detailed on accessible site content.

NeuroSync develops objective, AI-powered digital health solutions for brain health assessment and performance optimization. The company's flagship product, EYE-SYNC, is an FDA-cleared platform that delivers rapid, portable eye-tracking and oculomotor testing for concussion diagnosis, neuro health evaluation, and performance monitoring. The platform comprises XR (extended reality) hardware, proprietary software with AI analytics, and customizable clinical reporting. Assessments complete in under one minute with 0.9 test-retest reliability, leveraging validated proprietary algorithms and quantification methods. NeuroSync serves healthcare systems, clinical research organizations, sports medicine programs, military/active duty personnel, and biopharma CNS trials. The platform is deployed at leading academic medical centers (Massachusetts General Hospital, Texas Health, Houston Methodist), collegiate athletic programs (Rice University, Georgia Tech, Virginia Tech), specialty neurology clinics, vestibular therapy centers, and professional sports organizations. Solutions address the gap in objective diagnostics for neurological conditions affecting over 83 million Americans annually. The wireless, portable design enables deployment in clinical, research, athletic, and field settings. NeuroSync markets to clinicians, researchers, high-performance specialists, and military medical personnel seeking objective, rapid brain health metrics for diagnosis, monitoring, and therapeutic planning.

ZETA Surgical Inc. designs and manufactures AI-powered frameless neuronavigation systems for cranial surgery and neuromodulation procedures. The company's core platform, REALTRACK™, delivers real-time image-guided navigation with submillimeter accuracy and live continuous surgical guidance tracking patient movement at 20 times per second. The system eliminates the need for cranial pin fixation and general anesthesia, enabling bedside procedures in operating rooms, emergency settings, and ambulatory surgical centers. Primary clinical applications include external ventricular drain (ventriculostomy) placement, brain biopsy, transcranial magnetic stimulation (TMS) targeting, and tumor resection such as cavernoma removal. Clinical data demonstrates 100% single-pass catheter placement success for ventriculostomy (versus 81% freehand), 100% ideal placement (versus 32% freehand), zero adverse events and revision surgeries. The TMS Navigation System achieved FDA 510(k) clearance in October 2025. ZETA's technology integrates AI-based image analysis, ultra-fast system setup, and real-time guided intervention. The company is backed by leading neurosurgeons and research institutions including Harvard Medical School, Brigham and Women's Hospital, and Imperial College London. ZETA serves hospital operating rooms, neurosurgical centers, and interventional procedure suites primarily in the United States.

DePuy Synthes

DePuy Synthes is a prominent global company specializing in orthopaedic and neurological medical devices. Founded in 1895 in Warsaw, Indiana, it was the first commercial orthopaedic firm and has evolved significantly over the years. After merging with Synthes in 2012, it became part of Johnson & Johnson's MedTech segment, creating the world's largest orthopaedic corporation. The company offers a wide range of products, including knee and hip implants, bone fixation systems, spinal devices, and trauma products. DePuy Synthes is known for its innovative solutions in fracture repair, joint reconstruction, and neurosurgery. Its portfolio includes advanced surgical tools and biomaterials, enhancing its capabilities in the medical field. With key operations in Indiana, Switzerland, and Pennsylvania, DePuy Synthes serves healthcare providers, surgeons, and hospitals worldwide.

American Surgical Company is a U.S.-based innovator specializing in single-use neurosurgical instruments and surgical consumables manufactured with 100% wind-powered electricity. The company focuses on precision disposable tools designed for microsurgery, minimally invasive procedures, and complex cranial operations. Its product portfolio includes neurosurgical patties (DeliCot®, Ray-Cot®, Uniqcot™, Telfa®, Americot®, and tapered variants) engineered for optimal tissue protection and brain retraction with minimal trauma. Additional offerings include the ATLAS™ Choice Disposable Non-Stick Bipolar Forceps for precise coagulation with reduced thermal damage, RhinoStop™ nasal packing for hemostasis management, ComfortPack™ eye pledgets for ophthalmic procedures, and X-ray detectable cotton balls. With over 35 years of market presence, 98% customer retention, and endorsements from leading neurosurgeons and academic institutions, ASC serves over 70 countries across six continents. The company actively supports the neurosurgical community through educational initiatives, case studies, and professional engagements.

Delsys Inc. is a 30-year-old Massachusetts-based manufacturer of advanced wearable electromyography (EMG) systems and sensors for research, clinical diagnostics, and rehabilitation. The company specializes in wireless, real-time surface EMG technology with proprietary sensor designs and communication protocols optimized for human movement analysis, motor control research, neuromuscular physiology, and neurorehabilitation applications. Their primary product line—Trigno—comprises multiple system configurations (Centro for research-grade applications, Lite for entry-level systems, Link for integrated multimodal data acquisition, and HDsEMG for high-density motor unit analysis). Individual EMG sensors (Avanti, Mini, Duo, Quattro, Snap Lead) and auxiliary modules (Analog Adapter, FSR Adapter, Goniometer, Load Cell, EKG Biofeedback) enable customizable system builds. High-density EMG sensors (Galileo, Maize) support advanced motor unit decomposition and motor control studies. The Trigno ecosystem integrates with external research tools via a documented API and proprietary software (EMGworks, Trigno Discover, NeuroMap). Delsys serves academic institutions, medical research labs, rehabilitation facilities, exoskeleton/wearable robotics developers, and clinical diagnostics centers globally. Products emphasize low-noise signal acquisition, 40+ meter wireless range, intuitive data visualization and analysis workflows, and expandable architecture. The company provides remote and on-site training, technical support, and system integration services.

Jali Medical is a leading U.S. distributor of neuromodulation devices and wearable neurotechnologies, headquartered in Framingham, Massachusetts. Founded in 1991 with over 30 years of experience, the company specializes in non-invasive brain stimulation systems for neuroscience research and clinical applications. Jali Medical distributes FDA-cleared Transcranial Magnetic Stimulation (TMS) therapy systems for treating Major Depressive Disorder, along with advanced electroencephalography (EEG) systems, transcranial direct current stimulation (tDCS/tACS) devices, electromyography (EMG) systems, and neuronavigation equipment. The company serves academic institutions, research centers, hospitals, and clinicians nationwide, providing precision-engineered neurotechnology coupled with comprehensive scientific support. Jali Medical offers flexible leasing options for TMS therapy systems and in-person product demonstrations to facilitate clinical adoption and research innovation in neurophysiology and behavioral health applications.

M Dialysis AB is a Swedish medical device and research company specializing in clinical microdialysis solutions for intensive care monitoring and advanced pharmaceutical research. The company develops, manufactures, and markets a complete line of microdialysis instruments, consumables, and software used globally by hospitals, universities, and pharmaceutical companies for in vivo sampling and real-time monitoring of organs and tissues. M Dialysis serves clinicians and researchers seeking optimized patient care in ICU settings and accelerated drug development applications. The product portfolio includes the ISCUSflex microdialysis analyzer (the core analytical instrument), perfusion fluids, microvials, syringe kits, pump systems, and related consumables. The company is an offshoot of CMA Microdialysis AB, founded in 1984, and operates as a specialized provider in the narrow but clinically important niche of microdialysis technology. Applications span critical care monitoring, neurology, pharmacokinetics research, and tissue-specific biochemical assessment. The company maintains a global distribution network and serves as a research tool provider for pharmaceutical development and clinical decision support.

Integra LifeSciences Corporation is a global medical technology company specializing in surgical, neurologic, and regenerative care products. The company manufactures and distributes a comprehensive portfolio spanning neurosurgery (dural repair, cranial reconstruction, hydrocephalus management, CSF drainage systems, multimodal neuro-critical care monitoring), wound reconstruction and care (engineered collagen, fetal bovine dermis, urinary bladder matrix, amniotic tissue, Manuka honey dressings, total contact casting), surgical reconstruction (nerve and tendon repair, hernia repair, plastic and reconstructive surgery), surgical instrumentation and lighting (including brands Jarit®, MicroFrance®, Omni-Tract®, Ruggles®-Redmond™, Padgett®, and Miltex®), and ear, nose and throat devices (airway dilation systems, balloon sinuplasty, nasal dilation, Eustachian tube dilation, navigation systems). The company serves hospitals, surgery centers, and tissue banks globally. Integra maintains extensive international operations with customer service, repair, and medical inquiry support across North America, Europe, Asia-Pacific, and other regions. The company provides clinical documentation, IFUs (Instructions for Use), and regulatory support resources on its products portal.

HEMEDEX INC., founded in 2000, commercializes proprietary MIT-derived technology for real-time quantification of tissue perfusion and cerebral blood flow (CBF) at the capillary level. The company's patented thermal diffusion microprobe-based platform is designed for use in neurocritical care and neurosurgical settings, providing clinicians with continuous, absolute measurements of cerebral perfusion during complex procedures involving compromised vasculature, traumatic brain injury, subarachnoid hemorrhage, and other acute neurological conditions. The Bowman Perfusion Monitor enables bedside multimodal neuromonitoring for up to ten days, offering early warning of tissue ischemia and rapid assessment of intervention efficacy. ISO 13485:2012 certified medical device manufacturer serving leading academic medical centers and neuro ICUs across North America.

REEV is a medical robotics company specializing in personalized mobility solutions for individuals with neurological gait disorders, including stroke survivors, multiple sclerosis, and paraplegia patients. The company offers an integrated two-product platform: REEV SENSE, an AI-powered wearable gait analysis system that captures real-time kinematic data via dual sensors, and DREEVEN, a motorized knee-ankle-foot orthosis (KAFO) that provides personalized robotic assistance based on patient-specific gait signatures. The system enables certified orthotists and rehabilitation clinics to perform rapid gait calibration, monitor patient progression through mobile analytics, and deliver customized motor control assistance in outpatient and clinical settings. REEV's technology integrates electro-hydraulic actuation with machine learning algorithms to adapt orthotic support dynamically to each patient's walking pattern, improving functional mobility and independence.

ONWARD Medical is a clinical-stage medical device company developing non-invasive spinal cord stimulation therapies for people with spinal cord injury (SCI). The company's primary commercial product is the ARCEX System, a transcutaneous electrical spinal cord stimulation device FDA-cleared and CE-marked for improving hand sensation and strength in individuals with chronic cervical spinal cord injury (C2-C8). The ARCEX System comprises a wearable stimulator that delivers programmed electrical pulses via electrodes placed on the skin at the back of the neck, designed for use in conjunction with functional task practice in clinical rehabilitation settings and home-based exercise programs. The company has received 10 FDA Breakthrough Device Designations and holds nearly 400 issued or pending patents. Clinical evidence from the Up-LIFT study, published in Nature Medicine, demonstrated that 90% of 65 participants improved upper limb strength or function, with 87% reporting improved quality of life. ONWARD is also developing investigational therapies including ARCIM (implantable spinal cord stimulation) and ARCBCI (brain-computer interface combined systems), neither yet commercially available. The company collaborates with leading SCI research centers and rehabilitation organizations globally. Manufacturing and clinical delivery capabilities support both clinic-based and at-home patient use.

Cognision, operating as Neuronetrix Solutions, LLC, is an FDA-cleared medical technology company specializing in advanced EEG/ERP systems for objective evaluation of cognitive function. Founded in 2003, the company develops brain-based biomarker solutions for clinical assessment and pharmaceutical research. The COGNISION® System features a user-friendly EEG/ERP device with a comfortable headset for point-of-care testing, generating intuitive clinical reports. The technology is validated for assessing concussion, mild traumatic brain injury (mTBI), dementia, Alzheimer's disease, and other cognitive disorders. Cognision serves healthcare systems, private practices, universities, and global clinical trial sponsors, providing objective physiological measures of cognitive function for clinicians, researchers, and pharmaceutical companies conducting CNS drug development studies.